Darryl B Sampey

20100028940, Feb 4, 2010

May 18, 2006

11/914725

Luis Branco - Rockville MD, US
Darryl Sampey - Littlestown PA, US

BioFactura, Inc. - Rockville MD

C12P 21/06
C12N 15/63
C12N 5/10
C12N 5/02

435 691, 4353201, 435354, 435407

The present invention relates to novel selection marker vectors, and methods for using these vectors to generate stable gene expression systems in eukaryotic cells utilizing any enzyme useful in the eukaryotic sterol/cholesterol biosynthetic pathway, such as a 3-ketosteroid reductase, as a metabolic selection marker to select transfected cells. In one embodiment, the method comprises transfecting cells that are auxotrophic for cholesterol with a vector encoding 3-ketosteroid reductase and at least one heterologous protein, and selecting cells that have the ability to survive in medium lacking cholesterol and/or producing the heterologous protein in these cells in chemically defined and/or serum-free media.

20100261640, Oct 14, 2010

Apr 10, 2008

12/450756

Luis M. Branco - New Orleans LA, US
Alexander Matschiner - Rockville MD, US
Megan M. Illick - Gaithersburg MD, US
Darryl B. Sampey - Frederick MD, US
Robert F. Garry - New Orleans LA, US
Daniel G. Bausch - New Orleans LA, US
Joseph N. Fair - Knoxville MD, US
Mary C. Guttieri - Frederick MD, US
Kathleen A. Cashman - Purcellville VA, US
Russell B. Wilson - Mandeville LA, US
Peter C. Kulakosky - Metairie LA, US
F. Jon Geske - Commerce City CO, US

A61K 38/16
C07K 14/08
C07H 21/04
C12N 15/63
C07K 16/10
C12Q 1/70
C12P 21/02
A61P 31/14

514 37, 530395, 5303873, 536 2372, 4353201, 5303879, 435 5, 435 697

The invention discloses compositions comprising soluble and membrane-anchored forms of Lassa virus (LASV) glycoprotein 1 (GP1), glycoprotein 2 (GP2), the glycoprotein precursor (GPC), the nucleocapsid protein (NP), and the nucleic acids encoding these proteins. This invention further relates to diagnostic and preventative methods using these compositions. Preventative methods include preparation of vaccines, as well as factors (e.g. small molecules) that inhibit LASV infectivity. Further, the invention relates to diagnostic and therapeutic antibodies including neutralizing antibodies for the prevention and treatment of infection by LASV and other arenaviruses.

20120045827, Feb 23, 2012

Mar 9, 2009

13/255418

Darryl Sampey - Frederick MD, US

BIOFACTURA, INC. - Rockville MD

C12N 5/078
C12M 1/00

435325, 4352831

The present invention provides materials and methods for the isolation of immune cells. In one embodiment, the present invention provides a device for the isolation and separation of antigen-specific memory B cells. Immune cells will be separated by flowing the cells along a ligand-conjugated biopolymer surface. The ligand may be distributed in a concentration gradient along the z-axis of the biopolymer surface. Cells that display receptors specific for the ligands on the biopolymer will interact with the ligands and roll along the surface in the fashion of leukocyte rolling. Additive adhesive interactions will cause differential cell separation and eventual immobilization.

20140377740, Dec 25, 2014

Jan 30, 2014

14/168438

- New Orleans LA, US
Alexander MATSCHINER - Rockville MD, US
Megan M. ILLICK - Gaithersburg MD, US
Darryl B. SAMPEY - Frederick MD, US
Robert F. GARRY - New Orleans LA, US
Daniel G. BAUSCH - New Orleans LA, US
Joseph N. FAIR - Knoxville MD, US
Mary C. GUTTIERI - Frederick MD, US
Kathleen A. CASHMAN - Purcellville VA, US
Russell B. WILSON - Mandeville LA, US
Peter C. KULAKOSKY - Metairie LA, US
F. Jon GESKE - Commerce City CO, US

BIOFACTURA, INC. - Rockville MD
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND - New Orleans LA

C07K 14/005
G01N 33/569
C07K 16/10

435 5, 530395, 5303873

Soluble and membrane-anchored forms of Lassa virus (LASV) glycoprotein 1 (GP1), glycoprotein 2 (GP2), the glycoprotein precursor (GPC), the nucleocapsid protein (NP), and the nucleic acids encoding these proteins are disclosed, as well as diagnostic and preventative methods using these compositions. Also disclosed are methods including preparation of vaccines, factors (e.g. small molecules) that inhibit LASV infectivity, and diagnostic and therapeutic antibodies including neutralizing antibodies for the prevention and treatment of infection by LASV and other arenaviruses.